- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06372379
Development of a Multipurpose Dashboard to Monitor the Situation of Emergency Departments (eCREAM-UC2)
May 18, 2026 updated by: Mario Negri Institute for Pharmacological Research
Development of a Multipurpose Dashboard to Monitor the Situation of Emergency Departments. An Observational Prospective Study
An emergency department (ED) is a healthcare service that provides the first clinical assessment and treatment to patients with various acute conditions.
These departments, however, are often overwhelmed by the large volume of patients.
As a consequence, ED crowding has become a global concern and has been correlated to reduced timeliness and effectiveness of care and increased patient mortality.
Concerning input, 20% to 30% of patients are brought to the ED by ambulance; the remaining are self-presenting for the vast majority.
Notably, non-urgent conditions characterize a high proportion of all ED visits worldwide, and almost all of these visits involve self-presenting patients.
Increasing the awareness of these patients about the mandate of EDs and the real-time situation of the neighboring emergency departments has the potential to reduce the self-presentation of patients with minor, non-urgent conditions.
Such patient empowerment can be achieved through a dashboard.
Concerning throughput, working in the ED requires emergency physicians and nurses to treat many patients at once while maintaining situational awareness of the surroundings.
This is especially true for the head of the department, but it also holds for all physicians.
It can be crucial, for example, for physicians to know if there is a bottleneck in the flow of the entire patient care process, such as a particularly high average waiting time for radiology reporting or cardiologic consultation.
The availability of this information allows countermeasures to be put in place to regain efficiency.
All this can be achieved through dedicated dashboards automatically fed from various information system.
In addition, appropriate dashboards also enable health policymakers to monitor specific epidemiological phenomena, such as the emergence of certain infectious diseases, in a timely manner.
Study Overview
Study Type
Observational
Enrollment (Estimated)
162000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chiara Pandolfini
- Phone Number: 0039 02 39014 253
- Email: chiara.pandolfini@marionegri.it
Study Contact Backup
- Name: Giulia Ghilardi
- Phone Number: 0039 035 4535 389
- Email: giulia_irene.ghilardi@marionegri.it
Study Locations
-
-
-
Torino, Italy
- Recruiting
- Ospedale San Giovanni Bosco
-
Contact:
- Franco Aprà
- Phone Number: +39 0112402349
- Email: franco.apra@aslcittaditorino.it
-
Vercelli, Italy
- Recruiting
- Ospedale Sant'Andrea
-
Contact:
- Sergio Tartaglia
- Phone Number: +39 0161 593111
- Email: srtartaglia@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
All adult patients who arrived at participating emergency departments between January 1, 2025 and December 31, 2025
Description
Inclusion Criteria:
- Adult
- Arrived at emergency department between 1 January 2025 and 31 December 2025
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Adults who attended the emergency department
|
no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daschboards
Time Frame: September 2024 - September 2027
|
Develop three different control panels for three different end-users, specifically:
|
September 2024 - September 2027
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Guido Bertolini, MD, Istituto Di Ricerche Farmacologiche Mario Negri
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 22, 2025
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
February 1, 2027
Study Registration Dates
First Submitted
April 9, 2024
First Submitted That Met QC Criteria
April 12, 2024
First Posted (Actual)
April 18, 2024
Study Record Updates
Last Update Posted (Actual)
May 20, 2026
Last Update Submitted That Met QC Criteria
May 18, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8780_UC2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The anonymized data derived from this study could be shared for secondary use in the context of research projects.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Emergency Medicine
-
Samsung Medical CenterRecruitingEmergency Medicine | Medical Informatics | Pediatric Emergency MedicineKorea, Republic of
-
Universiti Sains MalaysiaEnrolling by invitationEmergency Medicine | Regional AnaesthesiaMalaysia
-
RWTH Aachen UniversityCompletedTelemedicine | Disaster Medicine | Emergency MedicineGermany
-
Washington University School of MedicineEpharmix, Inc.CompletedEmergency Medicine | Mobile Health | General MedicineUnited States
-
Mario Negri Institute for Pharmacological ResearchCentre Hospitalier Universitaire Vaudois; Fondazione Bruno Kessler; Astir s.r.l. and other collaboratorsRecruitingEmergency MedicineItaly
-
Guangdong Provincial People's HospitalRecruiting
-
Massachusetts General HospitalTerminatedEmergency MedicineUnited States
-
Ataturk UniversityCompletedEmergency MedicineTurkey
-
University of AarhusAarhus University Hospital; Herning Hospital; Horsens Hospital; Randers Regional... and other collaboratorsCompleted
Clinical Trials on no intervention
-
Hopital FochNot yet recruitingInterstitial Lung DiseaseFrance
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
Huashan HospitalZhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Tongji Hospital; Qilu Hospital... and other collaboratorsRecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in VitroChina
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of Dublin, Trinity CollegeCompleted